Search Medical Condition
Please enter condition
Please choose location from dropdown

Le Mans Cedex 02, France Clinical Trials

A listing of Le Mans Cedex 02, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (145) clinical trials

Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS

Polymyalgia rheumatic (PMR) is a frequent inflammatory disease. It affects the elderly, with peak incidences at the age of 70 to 80 years; an age >50 years or older, is considered a criterion for the diagnosis. Polymyalgia rheumatica occurs at a frequency that is 3 to 10 times that of …

Phase

0.0 miles

Learn More »

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed Stage III Subjects With Locally Advanced Unresectable Non-small Cell Lung Cancer

This is a Phase 3, randomized, double-blind, placebo-controlled multicenter global study designed to compare the efficacy and safety of tislelizumab in combination with concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy versus cCRT alone, and tislelizumab given sequentially after cCRT versus cCRT alone, in newly diagnosed stage III subjects with locally …

Phase

0.0 miles

Learn More »

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer arising from the mesothelial surface of the pleura. In Europe, the incidence is about 20 per million and is almost always caused by asbestos exposure, with a usual lag time of 30 years between exposure and presentation. Patients diagnosed with …

Phase

0.0 miles

Learn More »

A Study of the Impact of Apremilast (CC-10004) on Quality of Life Efficacy and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life

This is a Phase 4, multi-center, randomized, placebo-controlled, double-blind study of the impact of apremilast on quality of life, efficacy, and safety in subjects with manifestations of plaque psoriasis and impaired quality of life. Approximately 255 subjects will be randomized 2 (apremilast):1 (placebo) in approximately 6 to 10 countries in …

Phase

0.0 miles

Learn More »

ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

This is a global, multicenter open-label, single-arm, Phase 2 study of the PI3K inhibitor ME-401 in subjects with relapsed/refractory follicular lymphoma after failure of at least 2 prior lines of systemic therapy which must have included an anti-CD20 antibody and chemotherapy with an alkylating agent or a purine analogue. Approximately …

Phase

0.0 miles

Learn More »

Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy.

This is a Phase III, randomized, double-blind, placebo controlled, study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 treatment, compared to placebo, in patients with early stage TNBC at high risk for recurrence.

Phase

0.0 miles

Learn More »

Protecting Kidneys Through a Low Protein Diet: A Stepwise Multiple-Choice System Approach

The recent paradigm on dialysis start suggests that an intention to defer policy should be preferred to beginning dialysis early ("the earliest the best" strategy). This strategy is further supported by the consideration that patient profiles are changing with the increasing proportion of older and higher comorbidity patients. In high …

Phase N/A

0.0 miles

Learn More »

An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Crizotinib

The drug being tested in this study is called brigatinib. Brigatinib has been demonstrated to benefit people with ALK+ NSCLC. The comparator drug is called alectinib. Alectinib has been demonstrated to benefit people with ALK+ NSCLC. Both drugs belong to a class of drugs called anaplastic lymphoma kinase (ALK) inhibitors. …

Phase

0.0 miles

Learn More »

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

This is a global, Phase 3, randomized study of zanubrutinib versus ibrutinib in approximately 600 participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The primary efficacy endpoint is overall response rate determined by investigator assessment. Participants will be randomized in a 1:1 manner to either zanubrutinib or ibrutinib. …

Phase

0.0 miles

Learn More »

Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump

The aim of this study is to compare SmartGuard function with captor and insulin pump to improve the glycemia stability in real condition. There are several phases: phase 1: insulin pump without captor (12 weeks) phase 2: insulin pump with captor and without SmartGuard function (4X6 days; 4 weeks) phase …

Phase N/A

0.0 miles

Learn More »